CN111148534A - 抗igf和抗pd-1抗癌组合疗法 - Google Patents

抗igf和抗pd-1抗癌组合疗法 Download PDF

Info

Publication number
CN111148534A
CN111148534A CN201880063798.0A CN201880063798A CN111148534A CN 111148534 A CN111148534 A CN 111148534A CN 201880063798 A CN201880063798 A CN 201880063798A CN 111148534 A CN111148534 A CN 111148534A
Authority
CN
China
Prior art keywords
ser
compound
val
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880063798.0A
Other languages
English (en)
Chinese (zh)
Inventor
U·魏尔·切尔尼洛夫斯基
M·雷斯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN111148534A publication Critical patent/CN111148534A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201880063798.0A 2017-09-29 2018-09-28 抗igf和抗pd-1抗癌组合疗法 Pending CN111148534A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17194196.6 2017-09-29
EP17194196 2017-09-29
PCT/EP2018/076494 WO2019063802A1 (en) 2017-09-29 2018-09-28 ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1

Publications (1)

Publication Number Publication Date
CN111148534A true CN111148534A (zh) 2020-05-12

Family

ID=60009481

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880063798.0A Pending CN111148534A (zh) 2017-09-29 2018-09-28 抗igf和抗pd-1抗癌组合疗法

Country Status (5)

Country Link
US (1) US20200239559A1 (enExample)
EP (1) EP3687573A1 (enExample)
JP (1) JP2020535180A (enExample)
CN (1) CN111148534A (enExample)
WO (1) WO2019063802A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112111575A (zh) * 2020-09-22 2020-12-22 任国胜 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用
CN114949228A (zh) * 2017-04-05 2022-08-30 勃林格殷格翰国际有限公司 抗癌组合疗法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3148291A1 (en) * 2019-09-11 2021-03-18 Boehringer Ingelheim Io Canada, Inc. Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017055291A1 (en) * 2015-09-28 2017-04-06 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2017151517A1 (en) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN103396487A (zh) * 2008-12-12 2013-11-20 贝林格尔.英格海姆国际有限公司 抗igf抗体
US20130122005A1 (en) * 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
HRP20192260T1 (hr) * 2014-01-24 2020-03-06 Boehringer Ingelheim International Gmbh Liječenje raka uporabom antagonista receptora faktora rasta nalik inzulinu (igf) u kombinaciji s eksemestanom i everolimusom
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017055291A1 (en) * 2015-09-28 2017-04-06 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2017151517A1 (en) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AARON SIMPSON等: "Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies", 《TARGET ONCOL.》 *
HASHEM O. ALSAAB等: "PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome", 《FRONTIERS IN PHARMACOLOGY》 *
K. DANE WITTRUP等: "Antitumor Antibodies Can Drive Therapeutic T Cell Responses", 《TRENDS CANCER》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114949228A (zh) * 2017-04-05 2022-08-30 勃林格殷格翰国际有限公司 抗癌组合疗法
CN112111575A (zh) * 2020-09-22 2020-12-22 任国胜 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用

Also Published As

Publication number Publication date
US20200239559A1 (en) 2020-07-30
JP2020535180A (ja) 2020-12-03
WO2019063802A1 (en) 2019-04-04
EP3687573A1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
CN108368174B (zh) 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
KR20170003575A (ko) 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
CN111629788A (zh) 用拮抗性抗-pd-1抗体治疗癌症的方法
KR20170004006A (ko) 암을 치료하기 위한 항-ｃｃｒ4 항체 및 4-1ｂｂ 효능제의 조합
CN105636986A (zh) 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
KR20200013231A (ko) 항암 조합 요법
JP2022512851A (ja) がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン
US20210317214A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
CN111148534A (zh) 抗igf和抗pd-1抗癌组合疗法
KR102239752B1 (ko) 종양 특이적 약물복합체와 항pd-l1 항체를 유효성분으로 하는 암 예방 또는 치료를 위한 병용 투여용 약학 조성물
EP3965816A1 (en) Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
US20240010729A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN111973739A (zh) 抗pd-l1单克隆抗体治疗癌症的用途
CN118765284A (zh) 结直肠癌的组合疗法
KR20240099362A (ko) 혈액암에 대한 lag-3 길항제 요법
CN116745322A (zh) 使用抗岩藻糖基-gm1抗体的组合疗法
WO2025036445A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
WO2024041652A1 (en) Methods of cancer treatment
TW202523693A (zh) 手術前後基於抗ｐｄ－１之治療
WO2024137776A1 (en) Combination therapy for lung cancer
EP4005593A1 (en) Multivariable dosing method for use in treating high-egfr expression cancer
WO2024163494A1 (en) Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
CN119053623A (zh) 用抗btla作为单一疗法或组合疗法治疗实体瘤的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200512

WD01 Invention patent application deemed withdrawn after publication